Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations.
作者信息
Di Caro Antonino, Cunha Flavia, Petrosillo Nicola, Beeching Nicholas J, Ergonul Oner, Petersen Eskild, Koopmans Marion P G
机构信息
European Society for Clinical Microbiology and Infectious Diseases (ESCMID), Emerging Infections Task Force, ESCMID, Basel, Switzerland; Laboratory of Microbiology, National Institute for Infectious Diseases 'Lazzaro Spallanzani', Rome, Italy; Department of Molecular Medicine, San Matteo Hospital, University of Pavia, Pavia, Italy.
European Society for Clinical Microbiology and Infectious Diseases (ESCMID), Emerging Infections Task Force, ESCMID, Basel, Switzerland; Department of Infectious Diseases, Coimbra Hospital and University Centre, Coimbra, Portugal.
出版信息
Clin Microbiol Infect. 2021 Jun;27(6):823-826. doi: 10.1016/j.cmi.2021.03.011. Epub 2021 Mar 29.
Abstract
摘要
相似文献
1
Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations.严重急性呼吸综合征冠状病毒2逃逸突变体以及自然感染或免疫接种产生的保护性免疫。
Clin Microbiol Infect. 2021 Jun;27(6):823-826. doi: 10.1016/j.cmi.2021.03.011. Epub 2021 Mar 29.
2
Vaccination of Pregnant Women Against COVID-19.孕妇接种 COVID-19 疫苗。
Neoreviews. 2021 Sep;22(9):e570-e573. doi: 10.1542/neo.22-9-e570.
3
Genetic Variants of SARS-CoV-2-What Do They Mean?新型冠状病毒2019（SARS-CoV-2）的基因变异——它们意味着什么？
JAMA. 2021 Feb 9;325(6):529-531. doi: 10.1001/jama.2020.27124.
4
How to redesign COVID vaccines so they protect against variants.如何重新设计新冠疫苗以使其能抵御变异毒株。
Nature. 2021 Feb;590(7844):15-16. doi: 10.1038/d41586-021-00241-6.
5
Pfizer COVID vaccine protects against worrying coronavirus variants.辉瑞新冠疫苗可预防令人担忧的新冠病毒变种。
Nature. 2021 May;593(7859):325-326. doi: 10.1038/d41586-021-01222-5.
6
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
7
Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2.重新利用儿童疫苗：我们能否训练免疫系统对抗 SARS-CoV-2。
Expert Rev Vaccines. 2021 Sep;20(9):1051-1057. doi: 10.1080/14760584.2021.1960161. Epub 2021 Aug 6.
8
9
Symptomatic SARS-CoV-2 infections after full schedule BNT162b2 vaccination in seropositive healthcare workers: a case series from a single institution.血清阳性医护人员完成 BNT162b2 全程接种后出现有症状的 SARS-CoV-2 感染：来自单一机构的病例系列研究。
Emerg Microbes Infect. 2021 Dec;10(1):1254-1256. doi: 10.1080/22221751.2021.1942230.
10
Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.从卡介苗（BCG）看新冠病毒候选疫苗。
J Infect Dis. 2021 Feb 3;223(2):189-191. doi: 10.1093/infdis/jiaa637.
引用本文的文献
1
The Impact of Demographic, Clinical Characteristics and the Various COVID-19 Variant Types on All-Cause Mortality: A Case-Series Retrospective Study.人口统计学、临床特征及各种新冠病毒变异类型对全因死亡率的影响：一项病例系列回顾性研究
Diseases. 2022 Nov 7;10(4):100. doi: 10.3390/diseases10040100.
2
Determination of COVID-19 PCR positivity and mutation status in coronaVac vaccinated individuals in Turkey.土耳其科兴新冠疫苗接种者的 COVID-19 PCR 阳性率和突变情况的测定。
Turk J Med Sci. 2022 Jun;52(3):541-546. doi: 10.55730/1300-0144.5344. Epub 2022 Jun 16.
3
SARS-CoV-2 coinfections with variant genomic lineages identified by multiplex fragment analysis.通过多重片段分析鉴定的SARS-CoV-2与变异基因组谱系的合并感染。
Front Genet. 2022 Sep 26;13:942713. doi: 10.3389/fgene.2022.942713. eCollection 2022.
4
Differentiation of SARS-CoV-2 Variants Using RT-qPCRs by Targeting Recurrent Mutation Sites: A Diagnostic Laboratory Experience from Multi-Center Regional Study, August 2020-December 2021, Poland.利用针对反复出现突变位点的 RT-qPCR 对 SARS-CoV-2 变体进行区分：2020 年 8 月至 2021 年 12 月，波兰多中心区域研究中的诊断实验室经验。
Int J Mol Sci. 2022 Aug 20;23(16):9416. doi: 10.3390/ijms23169416.
5
Immune Response to SARS-CoV-2 Vaccines.对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的免疫反应
Biomedicines. 2022 Jun 21;10(7):1464. doi: 10.3390/biomedicines10071464.
6
Neutralization or enhancement of SARS-CoV-2 infection by a monoclonal antibody targeting a specific epitope in the spike receptor-binding domain.针对刺突受体结合域中特定表位的单克隆抗体对 SARS-CoV-2 感染的中和或增强作用。
Antiviral Res. 2022 Apr;200:105290. doi: 10.1016/j.antiviral.2022.105290. Epub 2022 Mar 13.
7
Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.中和单克隆抗体通过阻断膜融合抑制 SARS-CoV-2 感染。
Microbiol Spectr. 2022 Apr 27;10(2):e0181421. doi: 10.1128/spectrum.01814-21. Epub 2022 Mar 16.
8
A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.SARS-CoV-2 及其具有逃逸突变的新兴变异株的免疫逃逸、抗体逃逸、部分疫苗逃逸的详细概述。
Front Immunol. 2022 Feb 9;13:801522. doi: 10.3389/fimmu.2022.801522. eCollection 2022.
9
Emerging SARS-CoV-2 Genotypes Show Different Replication Patterns in Human Pulmonary and Intestinal Epithelial Cells.新兴的 SARS-CoV-2 基因型在人肺和肠道上皮细胞中的复制模式存在差异。
Viruses. 2021 Dec 23;14(1):23. doi: 10.3390/v14010023.
10
Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike.P681H突变对严重急性呼吸综合征冠状病毒2变异株B.1.1.7（阿尔法）刺突蛋白的蛋白水解激活的功能评估。
iScience. 2022 Jan 21;25(1):103589. doi: 10.1016/j.isci.2021.103589. Epub 2021 Dec 10.
本文引用的文献
1
Interpreting vaccine efficacy trial results for infection and transmission.解读感染和传播疫苗效力试验结果。
Vaccine. 2021 Jul 5;39(30):4082-4088. doi: 10.1016/j.vaccine.2021.06.011. Epub 2021 Jun 12.
2
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的B.1.1.7和B.1.351刺突变异体与人类血管紧张素转换酶2（ACE2）的结合亲和力增强。
Lancet Infect Dis. 2021 Aug;21(8):1070. doi: 10.1016/S1473-3099(21)00262-0. Epub 2021 May 19.
3
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
4
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.
5
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England.在英格兰，估计 SARS-CoV-2 谱系 B.1.1.7 的传染性和影响。
Science. 2021 Apr 9;372(6538). doi: 10.1126/science.abg3055. Epub 2021 Mar 3.
6
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape.SARS-CoV-2 刺突糖蛋白的反复缺失可导致抗体逃逸。
Science. 2021 Mar 12;371(6534):1139-1142. doi: 10.1126/science.abf6950. Epub 2021 Feb 3.
7
Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases.新冠病例中SARS-CoV-2表位的T细胞免疫显性和免疫流行率的综合分析。
Cell Rep Med. 2021 Feb 16;2(2):100204. doi: 10.1016/j.xcrm.2021.100204. Epub 2021 Jan 26.
8
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence.尽管血清阳性率很高，巴西玛瑙斯仍出现新冠病毒的卷土重来。
Lancet. 2021 Feb 6;397(10273):452-455. doi: 10.1016/S0140-6736(21)00183-5. Epub 2021 Jan 27.
9
Insights from SARS-CoV-2 sequences.来自严重急性呼吸综合征冠状病毒2（SARS-CoV-2）序列的见解。
Science. 2021 Jan 29;371(6528):466-467. doi: 10.1126/science.abf3995.
10
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic.在巴西亚马逊地区基本未采取缓解措施的情况下，SARS-CoV-2 的四分之三发病率。
Science. 2021 Jan 15;371(6526):288-292. doi: 10.1126/science.abe9728. Epub 2020 Dec 8.
Zotero 插件